Karyopharm Therapeutics reported $-116338000 in Equity Capital and Reserves for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Amgen AMGN:US $ 2419M 1503M
AstraZeneca AZN:LN 35932M 408M
Astrazeneca AZN:US $ 35932M 408M
Biocryst Pharmaceuticals BCRX:US $ -213.23M 49.02M
Bristol Myers Squibb BMY:US $ 32600M 1020M
Eli Lilly And LLY:US $ 8544.7M 786.1M
Enanta Pharmaceuticals ENTA:US $ 338.02M 20.56M
GlaxoSmithKline GSK:LN 16374M 193M
Karyopharm Therapeutics KPTI:US $ -116338000 33.26M
Macrogenics MGNX:US $ 142.48M 35.73M
Nektar Therapeutics NKTR:US $ 458.73M 149.16M
Novartis NOVN:VX SF 62925M 1385M
Novartis NVS:US $ 62925M 1385M
Regeneron Pharmaceuticals REGN:US $ 20687.8M 773.1M
Sangamo Biosciences SGMO:US $ 318.28M 16.24M
Takeda 4502:JP Y 6316832M 633813M
Tg Therapeutics TGTX:US $ 129.04M 41.35M
Ultragenyx Pharmaceutical RARE:US $ 678.07M 118.35M
Xencor XNCR:US $ 742.34M 20.68M
YTE INCY:US $ 4085.06M 221.99M